Salivary Klebsiella pneumoniae (Kp94) from periodontitis patients exacerbates diabetes by suppressing the intestinal ILC3/IL-22 pathway, impairing mucosal immunity and endocrine function, and IL-22 administration rescues these metabolic defects.
Key Findings
Results
Klebsiella pneumoniae (Kp94) isolated from salivary microbiota of periodontitis patients induced gut microbiota dysbiosis and systemic glucose intolerance in mice.
Kp94 was isolated from the salivary microbiota of periodontitis patients and administered via oral gavage following ligation-induced periodontitis in mice.
Systemic metabolic status was assessed using the Disease Activity Index (DAI), intraperitoneal glucose tolerance test (IPGTT), and measurements of serum total cholesterol (TC) and glycated hemoglobin (HbA1c).
Kp94 exposure resulted in measurable gut microbiota dysbiosis as characterized by 16S rRNA sequencing of intestinal contents.
Systemic glucose intolerance was demonstrated through IPGTT results in Kp94-exposed animals.
Results
Kp94 suppressed the intestinal ILC3/IL-22 pathway, reducing the proportion of ILC3s and impairing intestinal mucosal immunity.
Flow cytometry was used to analyze the proportion of ILC3s (group 3 innate lymphoid cells) in intestinal tissues.
Suppression of the ILC3/IL-22 pathway was identified as a mechanistic link between Kp94 exposure and intestinal immune impairment.
Transcriptomic analysis of intestinal tissues was performed to investigate underlying mechanisms.
The suppression of this pathway was associated with reduced antimicrobial peptide expression, specifically BD3 and LCN2.
Results
Kp94-mediated suppression of the ILC3/IL-22 pathway disrupted the intestinal mucus barrier and increased intestinal permeability.
Intestinal immunity was evaluated by immunohistochemistry and immunofluorescence.
Reduced antimicrobial peptide expression (BD3 and LCN2) was associated with disruption of the mucus barrier.
Increased intestinal permeability was observed as a consequence of impaired mucosal immunity.
These structural and functional intestinal defects were mechanistically linked to Kp94-induced suppression of IL-22 signaling.
Results
Kp94 suppression of the ILC3/IL-22 pathway inhibited intestinal endocrine function, notably reducing GLP-1 production.
GLP-1 (glucagon-like peptide-1) production was notably reduced as part of the endocrine dysfunction associated with Kp94 exposure.
This inhibition of endocrine function was identified as a concomitant consequence of ILC3/IL-22 pathway suppression.
The reduction in GLP-1 represents a potential mechanism by which periodontitis-associated Kp94 could exacerbate metabolic syndrome and diabetes.
Results
Exogenous IL-22 administration rescued Kp94-induced intestinal and metabolic defects by alleviating endoplasmic reticulum stress.
IL-22 administration was tested as a therapeutic intervention in the Kp94-exposed mouse model.
IL-22 rescued defects by alleviating endoplasmic reticulum (ER) stress, thereby restoring barrier and endocrine integrity.
Metabolic parameters including HbA1c were improved following IL-22 treatment.
The rescue effect confirmed that suppression of the ILC3/IL-22 pathway was causally involved in the metabolic and intestinal pathology induced by Kp94.
Conclusions
The intestinal ILC3/IL-22 pathway was identified as a potential mechanistic link and therapeutic target for metabolic and pancreatic damage associated with periodontitis-related diabetes.
Findings were derived from a murine model combining ligation-induced periodontitis with oral gavage of Kp94.
The study connects salivary pathobiont translocation to intestinal immune dysregulation and systemic metabolic consequences.
The authors propose the ILC3/IL-22 pathway as a therapeutic target for periodontitis-associated diabetes.
Pancreatic damage was also implicated as part of the downstream consequences of Kp94-induced ILC3/IL-22 suppression.
What This Means
This research suggests that a bacterium called Klebsiella pneumoniae (Kp94), found in the saliva of people with gum disease (periodontitis), may make diabetes worse by disrupting the immune defenses and hormone-producing functions of the gut. In mouse experiments, researchers introduced this bacterium orally and found it threw off the balance of gut bacteria, impaired a specific immune signaling pathway (involving immune cells called ILC3s and a protein called IL-22), weakened the protective mucus lining of the intestine, and reduced production of a blood sugar-regulating hormone called GLP-1. Together, these effects led to worsened blood sugar control, as measured by markers like HbA1c and glucose tolerance tests.
The study further found that the damage caused by Kp94 operated through a process called endoplasmic reticulum stress inside intestinal cells, and that giving mice extra IL-22 reversed many of these harmful effects — restoring the gut barrier, improving hormone production, and improving metabolic measurements including blood sugar control. This suggests the ILC3/IL-22 immune pathway is a critical link between gum disease and diabetes progression.
This research matters because it offers a potential biological explanation for why people with periodontitis have higher rates of diabetes and metabolic disease. It suggests that bacteria originating in the mouth can travel to the gut and interfere with immunity and metabolism, and that targeting the IL-22 immune pathway could be a future therapeutic strategy for people with both gum disease and diabetes. The findings highlight the importance of oral health as part of overall metabolic health.